



BIOARA

Bioara promotes development of new oriental medicine technology... Improved anti-diabetic effect using Cordyceps sinensis

Reporter Kim Jeong-ah jungya@chosun.com

Article entered 2022.06.15 11:14

The development of new oriental medicine using Cordyceps sinensis is being promoted.

Bioara Co., Ltd., a healthcare and natural new material research and development startup based on Cordyceps sinensis (Cordyceps), was selected for the '2022 Oriental Medicine Industry Advancement Support Project' for the development of new oriental medicine products and new technologies, and was supported by the Korea Oriental Medicine Promotion Agency, Pohang Biopark and Diabetes. They announced that they are collaborating to develop anti-diabetic Cordyceps sinensis products for patients.



Ara301 Cordyceps sinensis /Image provided by Bioara

In this project, we plan to develop a new technology that further improves the anti-diabetic effect by using Cordyceps sinensis. Cordyceps sinensis is known to be excellent for diabetes as it is rich in ingredients such as cordycepin, which has physiologically active effects and activates metabolism.

BioAra conducted an evaluation of the anti-diabetic function of 'Ara 301' Cordyceps sinensis conducted in 2021 with the Korea Oriental Medicine Promotion Agency, and found that Cordyceps sinensis contains high contents of cordycepin, adenosine, and beta-glucan, which have excellent immunity, anti-inflammatory, and anti-diabetic effects. It has been confirmed that it contains

Bioara CEO Kim Hyo-jeong said, "Cordyceps sinensis, which has boasted excellent efficacy as the herb of elixir since ancient times, has been shown to improve function.

"Continuous research and development is being conducted for this purpose," he said. "In this project, we are conducting research on Cordyceps sinensis using silkworms.

We are doing our best to research and do our best to provide an effective alternative to oriental medicine treatment for diabetes patients.

"I will," he said.